Alexa Fluor® 555 Anti-USP9x antibody [EPR13809(B)] - N-terminal,Abcam,AB312020
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Host
Rabbit
Reactivity
Human, Mouse
Application
Target Binding Affinity, Flow Cyt (Intra), Antibody Labelling, IHC-P, ICC/IF
Conjugate
Alexa Fluor® 555
Platform ID
BAB231944229
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Deubiquitinase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins (PubMed : 18254724, PubMed : 19135894, PubMed : 22371489, PubMed : 25944111, PubMed : 29626158, PubMed : 30914461, PubMed : 37454738). May therefore play an important regulatory role at the level of protein turnover by preventing degradation of proteins through the removal of conjugated ubiquitin (PubMed : 18254724, PubMed : 19135894, PubMed : 22371489, PubMed : 25944111, PubMed : 29626158, PubMed : 30914461, PubMed : 37454738). Specifically hydrolyzes 'Lys-11'-, followed by 'Lys-63'-, 'Lys-48'- and 'Lys-6'-linked polyubiquitins chains (PubMed : 30914461). Essential component of TGF-beta/BMP signaling cascade (PubMed : 19135894). Specifically deubiquitinates monoubiquitinated SMAD4, opposing the activity of E3 ubiquitin-protein ligase TRIM33 (PubMed : 19135894). Deubiquitinates alkylation repair enzyme ALKBH3 (PubMed : 25944111). OTUD4 recruits USP7 and USP9X to stabilize ALKBH3, thereby promoting the repair of alkylated DNA lesions (PubMed : 25944111). Deubiquitinates RNA demethylase enzyme ALKBH5, promoting its stability (PubMed : 37454738). Deubiquitinates mTORC2 complex component RICTOR at 'Lys-294' by removing 'Lys-63'-linked polyubiquitin chains, stabilizing RICTOR and enhancing its binding to MTOR, thus promoting mTORC2 complex assembly (PubMed : 33378666). Regulates chromosome alignment and segregation in mitosis by regulating the localization of BIRC5/survivin to mitotic centromeres (PubMed : 16322459). Involved in axonal growth and neuronal cell migration (PubMed : 24607389). Regulates cellular clock function by enhancing the protein stability and transcriptional activity of the core circadian protein BMAL1 via its deubiquitinating activity (PubMed : 29626158). Acts as a regulator of peroxisome import by mediating deubiquitination of PEX5 : specifically deubiquitinates PEX5 monoubiquitinated at 'Cys-11' following its retrotranslocation into the cytosol, resetting PEX5 for a subsequent import cycle (PubMed : 22371489). Deubiquitinates PEG10 (By similarity). Inhibits the activation of the Hippo signaling pathway via deubiquitination of AMOTL2 at 'Lys-347' and 'Lys-408' which prohibits its interaction with and activation of LATS2. Loss of LATS2 activation and subsequent loss of YAP1 phosphorylation results in an increase in YAP1-driven transcription of target genes (PubMed : 26598551, PubMed : 34404733). See full target information USP9X
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.